Immune Design: Merck buys Immune Designer for Immunotherapy Developer for $ 300M - February 22, 2019
Merck & Co. Inc. (MRK - Free Report) announced the acquisition of Immune Design's advanced immunotherapy company (IMDZ - Free Report) for $ 300 million in cash. Through this transaction, Merck, through a subsidiary, will acquire Immune Design at a... Continue Reading →
Read full article »
Immune Design develops immunotherapy product candidates for the treatment of cancer and chronic diseases.
Read more